132 related articles for article (PubMed ID: 31816821)
1. Changing Incidence and Stage Distribution of Prostate Cancer in a Lithuanian Population-Evidence from National PSA-Based Screening Program.
Patasius A; Smailyte G
Int J Environ Res Public Health; 2019 Dec; 16(23):. PubMed ID: 31816821
[TBL] [Abstract][Full Text] [Related]
2. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
[TBL] [Abstract][Full Text] [Related]
3. Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme.
Smailyte G; Aleknaviciene B
Public Health; 2012 Dec; 126(12):1075-7. PubMed ID: 22381571
[TBL] [Abstract][Full Text] [Related]
4. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
[TBL] [Abstract][Full Text] [Related]
6. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Houston KA; King J; Li J; Jemal A
J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
[TBL] [Abstract][Full Text] [Related]
7. Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia.
Luo Q; Yu XQ; Kahn C; Egger S; Patel MI; Grogan PB; Caruana M; Canfell K; Smith DP; O'Connell DL
Cancer Epidemiol; 2022 Jun; 78():102159. PubMed ID: 35447540
[TBL] [Abstract][Full Text] [Related]
8. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
[TBL] [Abstract][Full Text] [Related]
9. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
[TBL] [Abstract][Full Text] [Related]
10. Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: a population-based study.
Møller MH; Kristiansen IS; Beisland C; Rørvik J; Støvring H
BJU Int; 2016 Oct; 118(4):547-55. PubMed ID: 26497872
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
12. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
13. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
Jonsson H; Holmström B; Duffy SW; Stattin P
Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
[TBL] [Abstract][Full Text] [Related]
14. Long-term Trends in Prostate Cancer Incidence by Stage at Diagnosis in Japan Using the Multiple Imputation Approach, 1993-2014.
Saito E; Hori M; Matsuda T; Yoneoka D; Ito Y; Katanoda K
Cancer Epidemiol Biomarkers Prev; 2020 Jun; 29(6):1222-1228. PubMed ID: 32169995
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
16. Evidence of prostate cancer "reverse stage migration" toward more advanced disease at diagnosis: Data from the Pennsylvania Cancer Registry.
Reese AC; Wessel SR; Fisher SG; Mydlo JH
Urol Oncol; 2016 Aug; 34(8):335.e21-8. PubMed ID: 27108226
[TBL] [Abstract][Full Text] [Related]
17. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.
Schwartz KL; Severson RK; Gurney JG; Montie JE
Cancer; 1996 Sep; 78(6):1260-6. PubMed ID: 8826949
[TBL] [Abstract][Full Text] [Related]
18. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
19. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen.
Stephenson RA; Stanford JL
World J Urol; 1997; 15(6):331-5. PubMed ID: 9436281
[TBL] [Abstract][Full Text] [Related]
20. Recent trends in prostate cancer in Canada.
LeBlanc AG; Demers A; Shaw A
Health Rep; 2019 Apr; 30(4):12-17. PubMed ID: 30994922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]